West Pharmaceutical Services, Inc. - 2009 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: West Pharmaceutical Services, Inc.
Reporting Period: Fiscal year ended December 31, 2009.
Business Overview: West is a global manufacturer of components and systems for injectable drug delivery and plastic packaging. The company operates through two primary segments: Pharmaceutical Systems (packaging components, stoppers, seals, and safety systems) and Tech Group (custom injection molding for healthcare and consumer products).
Key Developments:
- Acquisition: Acquired Plastef Investissements SA (France) in July 2009 for $16.9 million cash plus contingent consideration, expanding safety syringe capabilities.
- Restructuring: Announced plans in November 2009 to exit specialized laboratory services and consolidate manufacturing, expecting $9.0 million in total charges and the elimination of approximately 100 positions.
- Realignment: Effective January 1, 2010, operations were realigned into "Pharmaceutical Packaging Systems" and "Pharmaceutical Delivery Systems" divisions.
Key Financial Metrics (2009)
| Metric | 2009 | 2008 | Change |
|---|---|---|---|
| Net Sales | $1,055.7 million | $1,051.1 million | +0.4% |
| Gross Profit | $303.6 million | $302.6 million | +0.3% |
| Gross Margin | 28.8% | 28.8% | - |
| Operating Profit | $97.5 million | $124.1 million | -21.4% |
| Operating Margin | 9.2% | 11.8% | -2.6 pts |
| Net Income (Continuing Ops) | $72.6 million | $86.6 million | -16.2% |
| Diluted EPS | $2.12 | $2.50 | -15.2% |
| Operating Cash Flow | $137.7 million | $135.0 million | +2.0% |
| Total Debt | $379.6 million | $386.0 million | -1.7% |
| Cash & Equivalents | $83.1 million | $87.2 million | -4.7% |
| Working Capital | $226.1 million | $207.1 million | +9.2% |
Material Changes vs. Prior Period
- Revenue Stability: Net sales remained flat year-over-year. Excluding unfavorable foreign currency translation ($32.5 million impact), organic sales grew 3.5% driven by price increases and the Plastef acquisition. The Pharmaceutical Systems segment grew 2.1%, while Tech Group declined 4.5% due to lower consumer product demand and resin cost pass-throughs.
- Profitability Decline: Operating profit decreased by $26.6 million. Key drivers included:
- Pension Costs: U.S. pension expense increased by $10.7 million due to the 2008 market decline in plan assets.
- Restructuring: $8.7 million in restructuring and related charges were recorded in 2009 (vs. $3.0 million in 2008).
- SG&A: Selling, General, and Administrative expenses rose $18.4 million, largely due to pension costs and IT system implementation.
- Foreign Currency: The strengthening U.S. dollar reduced reported revenues by $32.5 million and operating profit by $5.1 million compared to 2008.
- Tax Benefits: The effective tax rate dropped to 16.2% (from 21.6%) due to discrete tax benefits totaling $6.1 million, including a Brazilian tax amnesty benefit.
Guidance, Outlook, and Risks
2010 Outlook:
- Revenue: Management expects moderate revenue growth driven by volume/mix improvements and new product launches, partially offset by a slow economic recovery.
- Profitability: Operating profit growth is anticipated due to higher revenues, better product mix, and cost savings from restructuring initiatives.
- Capital Spending: Expected to be between $115 million and $130 million, focused on new products and expansion in China, the U.S., and Europe.
- Pension Costs: Expected to remain elevated but lower than 2009 levels.
- Economic Conditions: Recessionary pressures may lead to reduced customer inventories and delayed development projects.
- Raw Materials: Volatility in elastomer, aluminum, and plastic prices; reliance on single-source suppliers for critical materials.
- Regulatory: Potential U.S. healthcare legislation (e.g., medical device excise tax) and global regulatory changes could increase costs.
- Foreign Exchange: Significant exposure to the Euro, British Pound, and other currencies; 52% of sales are outside the U.S.
- Legal/Tax: Ongoing Brazilian tax litigation, though partially mitigated by a 2009 amnesty program.
Investor Verification Checklist
- Pension Assumptions: Verify the long-term rate of return assumption (7.75% for 2009) and discount rate (6.0%) used for U.S. pension plans, as these significantly impact operating expenses.
- Restructuring Execution: Monitor the realization of the estimated $9.0 million in restructuring charges and the associated $6.0 million in annual savings.
- Foreign Currency Hedging: Review the effectiveness of hedging strategies given the 52% international revenue exposure and recent dollar strength.
- Plastef Integration: Assess the performance of the Plastef acquisition and the achievement of milestones for contingent consideration.
- Healthcare Legislation: Evaluate the potential financial impact of pending U.S. healthcare reform, specifically regarding medical device taxes and benefit requirements.
- Order Backlog: Confirm the $238.7 million order backlog (as of Dec 31, 2009) and its conversion rate into 2010 revenue.